Background: Sublingual immunotherapy has been demonstrated to be able of inducing a regulatory T cell (Treg) response as evidenced by IL-10 production. Nasal obstruction may be measured by rhinomanometry. Objective: The aim of this study was to assess the association of sublingual immunotherapy-induced IL-10 production with nasal airflow resistances. Methods: 19 patients with perennial allergic rhinitis were studied: 9 successfully assumed sublingual immunotherapy for 3 years, 10 were considered as control. In vitro IL-10 production was evaluated after sublingual immunotherapy. Rhinomanometry was performed in all subjects before and after 3 years. Results: After 3 years, sublingual immunotherapy-patients showed a significant decrease of nas...
Th9 is a new T cell subset characterized by IL-9 production. It has been reported that serum IL-9 le...
BACKGROUND: Immunomodulatory effects of sublingual immunotherapy on systemic and mucosal mediators i...
BACKGROUND: Allergen-specific immunotherapy is the only curative treatment for type I allergy. It ca...
Background: Sublingual immunotherapy has been demonstrated to be able of inducing a regulatory T cel...
Sublingual immunotherapy (SLIT) has been shown to be capable of inducing a regulatory T-cell respons...
BACKGROUND: Sublingual immunotherapy (SLIT) has been demonstrated to be able of inducing immunologi...
Background: Subcutaneous specific immunotherapy has been demonstrated to be capable of inducing T-ce...
BACKGROUND: Allergic rhinitis is one of the most common allergic diseases and characterised by sneez...
Copyright © 2012 Takaya Yamada et al. This is an open access article distributed under the Creative ...
Background: The development of methods to predict the clinical effectiveness of sublingual immunothe...
The most common allergic diseases, such as rhinitis, asthma and atopic dermatitis, are sustained by ...
Background: Allergen-specific immunotherapy, including subcutaneous immunotherapy (SCIT) and subling...
Sublingual immunotherapy is safe and efficacious in the treatment of patients with allergic rhinitis...
Sublingual immunotherapy (SLIT) is an alternate route of administration of allergen-specific immunot...
BACKGROUND: Allergic rhinitis is one of the most common allergic diseases and characterised by sneez...
Th9 is a new T cell subset characterized by IL-9 production. It has been reported that serum IL-9 le...
BACKGROUND: Immunomodulatory effects of sublingual immunotherapy on systemic and mucosal mediators i...
BACKGROUND: Allergen-specific immunotherapy is the only curative treatment for type I allergy. It ca...
Background: Sublingual immunotherapy has been demonstrated to be able of inducing a regulatory T cel...
Sublingual immunotherapy (SLIT) has been shown to be capable of inducing a regulatory T-cell respons...
BACKGROUND: Sublingual immunotherapy (SLIT) has been demonstrated to be able of inducing immunologi...
Background: Subcutaneous specific immunotherapy has been demonstrated to be capable of inducing T-ce...
BACKGROUND: Allergic rhinitis is one of the most common allergic diseases and characterised by sneez...
Copyright © 2012 Takaya Yamada et al. This is an open access article distributed under the Creative ...
Background: The development of methods to predict the clinical effectiveness of sublingual immunothe...
The most common allergic diseases, such as rhinitis, asthma and atopic dermatitis, are sustained by ...
Background: Allergen-specific immunotherapy, including subcutaneous immunotherapy (SCIT) and subling...
Sublingual immunotherapy is safe and efficacious in the treatment of patients with allergic rhinitis...
Sublingual immunotherapy (SLIT) is an alternate route of administration of allergen-specific immunot...
BACKGROUND: Allergic rhinitis is one of the most common allergic diseases and characterised by sneez...
Th9 is a new T cell subset characterized by IL-9 production. It has been reported that serum IL-9 le...
BACKGROUND: Immunomodulatory effects of sublingual immunotherapy on systemic and mucosal mediators i...
BACKGROUND: Allergen-specific immunotherapy is the only curative treatment for type I allergy. It ca...